Sinvisc 2 ml syringe, 3 pcs.

Sinvisk is a chondroprotective drug that prostitutes synovial fluid. The drug consists of the active ingredient – hyaluronic acid derivative Gilan. The prosthesis is available as a visco-elastic solution in sterile syringes of 2 ml each.

Synvisc is a biological analogue of hyaluronate, a component of synovial fluid that provides the visco-elastic characteristics of intra-articular fluid. The mechanical properties of Gilan are superior to those of natural hyaluronate synovial fluid and hyaluronic acid solution at similar concentrations. Gilan is excreted from the body by the same ways as hyaluronate, the breakdown products of hyaluronate are not toxic.

Synvisc replenishes fluid viscosity, which improves the rheological and physiological state of the tissues of the diseased joint. Synvisk reduces pain and discomfort caused by dystrophic changes in cartilage tissues, thus improving mobility in the joint. The ability of the drug to protect cartilage from chemical and mechanical damage has been proven.

< br>.

Indications

Active ingredient

Composition

1 ml contains:

Hylan 8.0 mg;

Sodium chloride 8.5 mg;

Sodium hydrophosphate 0.16 mg;

sodium dihydrophosphate hydrate 0.04 mg;

water for injection.

How to take, the dosage

The Sinvisk injections must be performed exclusively in facilities officially certified for intra-articular injections, by licensed and certified physicians of the relevant profile and strictly in accordance with these instructions.

The recommended course of treatment with Sinvisk includes three injections into the cavity of the knee joint with an interval of 1 week. To achieve maximum effect, all three injections should be performed. The maximum recommended dose is six injections over six months with at least four weeks between courses.

The duration of effect in patients responding to treatment is usually at least twenty-six weeks, but more often than not, the time frame is longer. Treatment with Synvisc has an effect only on the affected joint where the drug is injected; there is no systemic effect with Synvisc.

Interaction

Don’t use disinfectants containing quaternary ammonium salts when treating the skin prior to injection.

Special Instructions

Sinvisk should not be injected if there is significant intra-articular effusion.

As with any invasive joint procedure, it is recommended that the patient be gentle and avoid excessive stress on the joint for several days following the Synvisc injection.

Sinvisk contains a small amount of chicken protein, so caution should be exercised when treating patients with related hypersensitivity.

The efficacy of a course of treatment containing fewer than three injections has not been established.

The efficacy and safety of Synvisc when used on joints other than the knee and for indications other than osteoarthritis have not been established.

Sinvisk has not been used to treat pregnant women or children under 18 years of age.

Anesthetics or other pharmacological agents should not be injected into the affected joint cavity during treatment with Synvisk.

Contraindications

Side effects

There may be transient pain, swelling in the injection area and/or the appearance of intra-articular exudation following a Synvisc injection. In some cases, the exudation may be significant and cause a more prolonged pain syndrome.

In these cases, it is necessary to perform a puncture of the joint and remove the exudate with subsequent microscopy to rule out infection and microcrystalline arthropathy (gout). Usually these reactions disappear within a few days and do not affect the effectiveness of treatment.

In clinical trials of the drug, no cases of infection were noted after Sinvisk injections, and only a few cases were reported in clinical use.